Braidwell LP purchased a new stake in shares of Alamar Biosciences, Inc. (NASDAQ:ALMR – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,083,983 shares of the company’s stock, valued at approximately $29,365,000. Braidwell LP owned about 1.56% of Alamar Biosciences at the end of the most recent quarter.
Separately, Wellington Management Group LLP bought a new stake in Alamar Biosciences in the 2nd quarter worth approximately $12,407,000.
Analysts Set New Price Targets
A number of research analysts have recently commented on ALMR shares. Stifel Nicolaus increased their target price on Alamar Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Zacks Research upgraded shares of Alamar Biosciences to a “hold” rating in a research report on Wednesday, May 13th. JPMorgan Chase & Co. upped their price target on shares of Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Leerink Partners began coverage on shares of Alamar Biosciences in a research report on Tuesday, May 12th. They set an “outperform” rating and a $35.00 price objective for the company. Finally, Weiss Ratings started coverage on shares of Alamar Biosciences in a research note on Tuesday, August 11th. They issued a “sell (d+)” rating for the company. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Alamar Biosciences currently has a consensus rating of “Hold” and an average price target of $31.80.
Alamar Biosciences Price Performance
Shares of NASDAQ ALMR opened at $30.49 on Thursday. Alamar Biosciences, Inc. has a 1 year low of $18.84 and a 1 year high of $38.54. The stock has a 50-day moving average price of $28.50. The company has a market capitalization of $2.12 billion and a P/E ratio of -15.56. The company has a current ratio of 11.85, a quick ratio of 10.23 and a debt-to-equity ratio of 0.03.
Alamar Biosciences (NASDAQ:ALMR – Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.14. The business had revenue of $29.43 million during the quarter. As a group, equities research analysts expect that Alamar Biosciences, Inc. will post -1.23 EPS for the current year.
About Alamar Biosciences
Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.
Featured Stories
- Five stocks we like better than Alamar Biosciences
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Want to see what other hedge funds are holding ALMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alamar Biosciences, Inc. (NASDAQ:ALMR – Free Report).
Receive News & Ratings for Alamar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alamar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
